← All organizations
Highest phase reached
Phase 3
Timeline
1990s
- Jan 1, 1999
Sorrento Therapeutics, Inc.— Founded
2010s
- Nov 8, 2016
Scilex Pharms Inc— Acquired - Mar 22, 2019
Semnur Pharmaceuticals, Inc.— Acquired
Drugs by trial phase (41 distinct, 81 trials)
Phase 4 (0 own, 1 via acquisition)
Phase 3 (8 own, 5 via acquisition)
Phase 2 (8 own, 2 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Amyloidosis
- Arthritis
- Arthritis, Rheumatoid
- Ascites
- Biliary Tract Neoplasms
- Cancer Pain
- Carcinoma
- Immunoglobulin Light-chain Amyloidosis
- Intractable Pain
- Lymphoma
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Mesothelioma
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Osteoarthritis
- Osteoarthritis, Knee
- Pancreatic Neoplasms
- Peritoneal Neoplasms
Marketed drugs (3)
Subsidiaries (3 direct, 3 total across the full acquisition tree)
Recent trials (50)
- NCT05692908Lead sponsorPhase 1Sep 30, 2023
- NCT05584709Lead sponsorPhase 1Mar 31, 2023
- NCT05361954Lead sponsorPhase 1Jan 31, 2023
- NCT05361954Study directorPhase 1Jan 31, 2023
- NCT05308225Lead sponsorPhase 1/Phase 2Dec 31, 2022
- NCT05361915Lead sponsorPhase 2Oct 31, 2022
- NCT05361915Study directorPhase 2Oct 31, 2022
- NCT05364840Study directorPhase 1Jun 7, 2022
- NCT05364840Lead sponsorPhase 1Jun 7, 2022
- NCT05372783Lead sponsorPhase 2Apr 4, 2022
- NCT05372783Study directorPhase 2Apr 4, 2022
- NCT05067257Lead sponsorPhase 2Dec 31, 2021
- NCT05060276Lead sponsorPhase 1Dec 31, 2021
- NCT05060276Study directorPhase 1Dec 31, 2021
- NCT05067257Study directorPhase 2Dec 31, 2021
Details
- Founded
- Glasgow, GB Jan 1, 1999
- Last known activity
- Sep 30, 2023
Notes
--- Pre-folding founded info: 2006-06-01 San Diego CA United States https://www.crunchbase.com/organization/sorrento-therapeutics ---